Abstract
We report here on a 24-year-old patient with Behçet’s disease who had been diagnosed with acute transverse myelitis. He was successfully treated with a combination regimen of a steroids, cyclophosphamide, and interferon-α. The treatment strategy with specific emphasis on interferon-α is discussed in the light of the pertinent literature.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akman-Demir G, Serdaroglu P, Tasci B, The Neuro-Behçet Study Group (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain 122:2171–2181
Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behçet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427
Assaad-Khalil S, Abou-Seif M, Abou-Seif S, El-Sewy F, El-Sewy M (1993) Neurologic involvement in Behçet’s disease: clinical, genetic and computed tomographic study. In: Wechsler B, Godeau P (eds) Behçet’s disease. Excerpta Medica International Congress Series, Amsterdam, pp 409–414
Transverse Myelitis Consortium Working Group (2002) Proposed diagnostic criteria and nosology of acute transverse myelitis Neurology 59:499–505
Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122:2183–2194
Ben Taarit C, Turki S, Ben Maiz H (2002) Neurological manifestations in Behcet’s disease. Forty observations in a cohort of 300 patients J Mal Vasc 27:77s–81s
Kalita J, Misra UK (2001) Is methyl prednisolone useful in acute transverse myelitis? Spinal Cord 39:471–476
Williams CS, Butler E, Roman GC (2001) Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 58:815–819
Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet’s disease—an update. Semin Arthritis Rheum 30:299–312
Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 134:1010–1016
Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G (1997) Interferon alpha for ocular Behcet’s disease Acta Ophthalmol Scand 75:720–722
Kötter I, Eckstein AK, Stübiger N, Zierhut M (1998) Treatment of ocular symptoms of Behcet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494
O’Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, Weyand C, Matteson E (1998) Interferon-alpha treatment of Behcet’s disease. J Rheumatol 25:1938–1944
Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D (1998) Efficacy and safety of systemic recombinant interferon-alpha in Behcet’s disease. J Intern Med 243:367–372
Azizlerli G, Sarica R, Kose A, Ovul C, Kavala M, Kayabali M, Erkan F, Kural Z (1996) Interferon alfa-2a in the treatment of Behcet’s disease. Dermatology 192:239–241
Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Direskeneli H, Akoglu T, Yazici H (1994) Systemic interferon alpha 2b treatment in Behcet’s syndrome. J Rheumatol 21:1098–1100
Alpsoy E, Yilmaz E, Basaran E (1994) Interferon therapy for Behcet’s disease. J Am Acad Dermatol 31:617–619
Çalgüneri M, Őztürk MA, Ertenli I, Kiraz S, Apraş S, Őzbalkan Z (2003) Effects of interferon alpha treatment on the clinical course of refractory Behçet’s disease. Ann Rheum Dis 62:492–493
Akman-Demir G, Baykan-Kurt B, Serdaroglu P, Gürvit H, Yurdakul S, Yazici H, Bahar S, Aktin E (1996) Seven-year follow-up neurological involvement in Behçet syndrome. Arch Neurol 53:691–694
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Çalgüneri, M., Onat, A.M., Öztürk, M.A. et al. Transverse myelitis in a patient with Behcet’s disease: favorable outcome with a combination of interferon-α. Clin Rheumatol 24, 64–66 (2005). https://doi.org/10.1007/s10067-004-0944-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-0944-1